Denise Myshko

Survodutide is a dual GLP-1/glucagon receptor agonist that was also able to normalize liver fat in 61% of patients with metabolic dysfunction-associated steatotic liver disease.

Hofstra University and Northwell Health’s jointly founded medical school has secured funding from the National Institutes of Health for its combined M.D./Ph.D. program.

Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, says that when used together, the numeric pain score and function scores give clinicians a far more complete clinical picture of a patient’s pain.

If approved, cemdisiran could be the first RNAi therapeutic to treat generalized myasthenia gravis that would be dosed every 12 weeks.

David Blair, CEO of LucyRx, and Jason Borschow, CEO of Abarca, spoke to Managed Healthcare Executive about the company’s merger and how the combined company is positioned for the PBM market of the future.

Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, argues that function-based tools offer a more equitable and clinically meaningful approach to pain management.

The merger is expected to close in the third quarter. Both PBMs will operate as wholly owned subsidiaries of Healthcare Revolution Partners.

Prior authorization and high out-of-pocket costs impact blood cancer patients' access to oral cancer drugs, according to a poster at the 2026 ASCO Meeting.

The FDA has set a target action date of July 29, 2026, for Lytenava to treat patients with wet age-related macular degeneration. Outlook Therapeutics had successfully appealed a complete response letter issued in December 2025.

The Veterans Affair’s Whole Health approach includes mindfulness, acupuncture, nutritional counseling, and a free app to help patients manage chronic pain.

Researchers analyzing seven oncology therapies found most U.S. commercial plans treat subcutaneous and IV formulations equally, but five payers enforced IV-preferred policies, according to a poster released at the 2026 ASCO meeting.

Demand for behavioral healthcare has surged, increasing costs for health plans and employers as millions of Americans deal with mental illness, substance use disorders and access challenges.

Nearly half of payers not covering GLP-1s for obesity say no price would change their minds on coverage, citing high costs, poor adherence, and weight regain concerns, finds a new survey by PSG.

Pfizer plans 10 phase 3 trials of berobenatide for chronic weight management and obesity-related comorbidities.

Romidepsin is approved to treat adults with cutaneous T-cell lymphoma. Ameal’s generic has received designation for 180 days of exclusivity.

Hospital pharmacy leaders cite a potential rebate model transition for the 340B program as one of their biggest worries amid rising manufacturer restrictions and evolving federal compliance requirements.

Real-world data presented at ASCO also show that at 12 month and 24 months, patients treated with Brukinsa had a higher probability of survival than those treated with other BTK inhibitors.

In an interview before the annual ASCO meeting, Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, talks about NOUS-209, an immunotherapy being studied to prevent cancer in those with Lynch syndrome mutations.

Eduardo Vilar-Sanchez, M.D., Ph.D., of the University of Texas MD Anderson Cancer Center, was awarded for his work in cancer immunoprevention and his efforts to develop a cancer vaccine for those who are carriers of Lynch mutations.

Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody that achieved 28-month median survival in advanced squamous non-small cell lung cancer.

Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone cancer patients.

A collagen implant that releases radiation after brain tumor surgery reduced cancer recurrence and increased overall survival, according to results presented at ASCO’s annual meeting.

Dana-Farber’s Katherine Janeway, M.D., discusses how molecular biomarkers inform treatment decisions in children and adolescents with the bone cancers Ewing sarcoma and osteosarcoma.

Afrezza is an inhaled insulin and the first needle-free insulin option for children with diabetes.

Hepcludex is an antiviral to treat adults living with chronic hepatitis D virus infection, a serious liver disease that occurs as a co-infection in people with chronic hepatitis B virus.

GLP-1 receptor agonist drugs may reduce cancer progression in lung, breast, colorectal, and liver cancers by 38% to 50%, and high GLP-1 receptor expression correlates with 33% lower mortality risk.

By targeting a specific pathway, the mineralocorticoid receptor, Kerendia is able to stop the cascade of inflammation and fibrosis that leads to kidney disease.

Milliman’s Medical Index finds delivery system consolidation, specialty drug growth, and site-of-care shifts are contributing to employee healthcare costs.

GLP-1 medications, especially for diabetes, will remain an influential cost driver in drug spending this year, supported by broader prescriber adoption and patient demand.